These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21646727)

  • 1. Possible targets of therapy for catecholaminergic polymorphic ventricular tachycardia. - Insight from a theoretical model -.
    Chan YH; Wu LS; Yeh YH; Wu CT; Wang CL; Luqman N; Chen WJ; Hsu TS; Kuo CT
    Circ J; 2011; 75(8):1833-42. PubMed ID: 21646727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation.
    Sung RJ; Lo CP; Hsiao PY; Tien HC
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1625-38. PubMed ID: 21742998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
    Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
    J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive Intracellular Na+ Excess in Purkinje Cells Promotes Arrhythmogenesis at Lower Levels of Stress Than Ventricular Myocytes From Mice With Catecholaminergic Polymorphic Ventricular Tachycardia.
    Willis BC; Pandit SV; Ponce-Balbuena D; Zarzoso M; Guerrero-Serna G; Limbu B; Deo M; Camors E; Ramirez RJ; Mironov S; Herron TJ; Valdivia HH; Jalife J
    Circulation; 2016 Jun; 133(24):2348-59. PubMed ID: 27169737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
    Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
    PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia.
    Tan Z; Xiao Z; Wei J; Zhang J; Zhou Q; Smith CD; Nani A; Wu G; Song LS; Back TG; Fill M; Chen SR
    Biochem J; 2016 Nov; 473(22):4159-4172. PubMed ID: 27623776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
    Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
    Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
    Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In the RyR2(R4496C) mouse model of CPVT, β-adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves.
    Kashimura T; Briston SJ; Trafford AW; Napolitano C; Priori SG; Eisner DA; Venetucci LA
    Circ Res; 2010 Dec; 107(12):1483-9. PubMed ID: 20966392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2.
    Xiong J; Liu X; Gong Y; Zhang P; Qiang S; Zhao Q; Guo R; Qian Y; Wang L; Zhu L; Wang R; Hao Z; Wen H; Zhang J; Tang K; Zang WF; Yuchi Z; Chen H; Chen SRW; Zheng W; Wang SQ; Xu YW; Liu Z
    J Mol Cell Cardiol; 2018 Apr; 117():26-35. PubMed ID: 29477366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of catecholaminergic polymorphic ventricular tachycardia.
    Györke S
    Heart Rhythm; 2009 Jan; 6(1):123-9. PubMed ID: 19121813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.
    Kontula K; Laitinen PJ; Lehtonen A; Toivonen L; Viitasalo M; Swan H
    Cardiovasc Res; 2005 Aug; 67(3):379-87. PubMed ID: 15913575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release.
    Radwański PB; Brunello L; Veeraraghavan R; Ho HT; Lou Q; Makara MA; Belevych AE; Anghelescu M; Priori SG; Volpe P; Hund TJ; Janssen PM; Mohler PJ; Bridge JH; Poelzing S; Györke S
    Cardiovasc Res; 2015 Apr; 106(1):143-52. PubMed ID: 25538156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.
    Zhang XH; Haviland S; Wei H; Sarić T; Fatima A; Hescheler J; Cleemann L; Morad M
    Cell Calcium; 2013 Aug; 54(2):57-70. PubMed ID: 23684427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
    Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
    Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
    Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
    J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia.
    Nishimura S; Yamamoto T; Nakamura Y; Kohno M; Hamada Y; Sufu Y; Fukui G; Nanno T; Ishiguchi H; Kato T; Xu X; Ono M; Oda T; Okuda S; Kobayashi S; Yano M
    Heart Rhythm; 2018 Jun; 15(6):905-914. PubMed ID: 29427818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.